At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Aug 29, 2026 at 10:30 ET
Cytokinetics presented positive additional Phase 3 results at ESC 2026 showing aficamten (MYQORZO) improves cardiac structure and diastolic function in non-obstructive HCM and outperforms metoprolol across pre-trial treatment groups in obstructive HCM. The company plans to submit a supplemental NDA for the nHCM indication in Q4 2026, expanding the drug's potential addressable market beyond the currently approved oHCM population.
- Additional ACACIA-HCM results showed aficamten significantly improved diastolic function (peak E velocity, septal e' velocity) and reduced left ventricular wall thickness (-0.2 cm, p<0.001) in nHCM at up to 72 weeks.
- MAPLE-HCM post-hoc analysis showed aficamten improved pVO2 vs metoprolol irrespective of prior beta-blocker use (no beta blockers: +3.1 mL/kg/min, p<0.001; on beta blockers: +1.9 mL/kg/min, p<0.001).
- Cytokinetics plans to submit a Supplemental New Drug Application for aficamten in non-obstructive HCM in Q4 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access